VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor

Neuropeptides

Volumn 30, Issue 5, 1996, Pages 491-496

  Vertongen, P ^a   Camby, I ^a   Darro, F ^a   Kiss, R ^a   Robberecht, P ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029861717     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(96)90015-3     Document Type: Article

References (31)

1. Christophe J. Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim Biophys Acta 1993; 1154: 183-199.
2. Rawlings SR. PACAP, PACAP receptors, and intracellular signalling. Mol Cell Endocrinol 1994; 101: C5-C9.
3. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992; 8: 811-819.
4. Couvineau A, Rouyer-Fessard C, Darmoul D et al. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 1994; 200: 769-776.
5. 2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993; 334: 3-8.
6. Inagaki N, Yoshida H, Mizuta M et al. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci USA 1994; 91: 2679-2683.
7. Svoboda M, Tastenoy M, Van Rampelbergh J et al. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 1994; 205: 1617-1624.
8. Robberecht P, Waelbroeck M, De Neef P et al. A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. FEBS Lett 1988; 228: 351-355.
9. 1 lymphoma cells: evidence for receptor glycosylation. J Receptor Res 1991; 11: 831-848.
10. Suda K, Smith DM, Ghatei MA, Bloom SR. Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain. Neurosci Lett 1992; 137: 19-23.
11. Tatsuno I, Yada T, Vigh S, Hidaka H, Arimura A. Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide increase cytosolic free calcium concentration in cultured rat hippocampal neurons. Endocrinology 1992; 131: 73-81.
12. Gottschall PE, Tatsuno I, Arimura A. Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res 1994; 637: 197-203.
13. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-2870.
14. Vertongen P, D'Haens J, Michotte A et al. Expression of pituitary adenylate cyclase activating polypeptide and receptors in human brain tumors. Peptides 1995; 16: 713-719.
15. Nielsen FC, Gammeltoft S, Westermark B, Fahrenkrug J. High affinity receptors for vasoactive intestinal peptide on a human glioma cell line. Peptides 1990; 11: 1225-1231.
16. Ciccarelli E, Vilardaga J-P, De Neef P et al. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul Pept 1994; 54: 397-407
17. Ciccarelli E, Svoboda M, De Neef P et al. Pharmacological properties of two recombinant splice variants of the PACAP type I receptor transfected and stably expressed in CHO cells. Eur J Pharmacol 1995; 288: 259-267
18. Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem 1974; 58: 541-548.
19. Sreedharan SP, Patel DR, Huang J-X, Goetzl EJ. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 1993; 193: 546-553.
20. Ogi K, Miyamoto Y, Masuda Y et al. Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor. Biochem Biophys Res Commun 1993; 196: 1511-1521.
21. Pauwels O, Kiss R. Digital morphonuclear analyses of sensitive versus resistant neoplastic cells to vinca-alkaloid, alkylating, and intercalating drugs. Cytometry 1991; 12: 388-397.
22. Bhat NR, Hauser KF, Kindy MS. Cell proliferation and protooncogene induction in oligodendroglial progenitors. J Neurosci Res 1992; 32: 340-349.
23. Robberecht P, Gourlet P, Vertongen P, Svoboda M. Characterization of the VIP receptor from the SUP T1 lymphoblasts. Adv Neuroimmunol 1996; 6: 49-57.
24. Chedeville A, Mirossay L, Chastre E, Hurbain-Kosmath I, Lopez M, Gespach C. Interaction of VIP, PACAP and related peptides in normal and leukemic human monocytes and macrophages. FEBS Lett 1993; 319: 171-176.
25. Luis J, Said SI. Characterization of VIP- and Helodermin-preferring receptors on human small cell lung carcinoma cell lines. Peptides 1990; 11: 1239-1244.
26. Rubinstein LV, Shoemaker RH, Paull KD et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990; 82: 1113-1118.
27. Vistica DT, Skehan P, Scuderio D, Monks A, Pittman A, Boyd MR. Tetrazolium-based for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 1991; 51: 2515-2520.
28. 6-dibutyryladenosine 3′, 5′-monophosphate, phorbol 12-myristate 13-acetate and by the polypeptide itself in human neuroblastoma cells, IMR-32. Eur J Biochem 1994; 223: 147-153.
29. Goossens JF, Manechez D, Pommery N, Formstecher P, Hénichart JP. VIP potentiates retinoic-acid effect on tissue transglutaminase activity in human neuroblastoma, the SK-N-SH cells. Neuropeptides 1993; 24: 99-103.
30. i and inositol phosphates in human neuroblastoma NB-OK-1 cells. Peptides 1993; 14: 1111-1118.
31. il-2. J Biol Chem 1994; 269: 15977-15980.